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ABSTRACT 
“Liquisolid Technique” considered as new technique to enhance solubility and dissolution rate of poorly water soluble drugs. These 
formulations are prepared by mixing drug in liquid state (solution, suspension or emulsion using non-volatile solvent) with carrier 
and coating material to form dry, free-flowing, readily compressible powder. In the current research work liquisolid technique is 
employed to enhance solubility and dissolution of antihypertensive drug Valsartan, which is poorly water soluble (0.021mg/ml) 
possessing very low bioavailability of 23%. Liquisolid formulation VLS9, containing Tween 80 (non-volatile solvent), Avicel 
PH102 (carrier) and Aerosil 200 (coating material) showed better flow properties and high in-vitro dissolution profile.  
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INTRODUCTION: 
Solubility is one of the key parameters to achieve 
desired concentration of drug in systemic circulation for 
showing affective pharmacological response. Low 
aqueous solubility is the major problem with 
formulation development of new chemical entities. 
Solubility enhances dissolution which in turn may 
increase bioavailability of poorly water soluble drugs. 
“Liquisolid Technique” also known as “Powder 
Solution Technology” is considered new, safe and 
economic technique to enhance solubility and 
dissolution profile of poorly water soluble drugs. 
Liquisolid formulations are prepared by converting 
liquid drug or drug in liquid state (solution, suspension 
or emulsion using non-volatile solvent) into dry, non-
adherent, free-flowing, readily compressible powder by 
blending liquid medication with carrier and coating 
materials. Due to their significantly improved wetting 
properties a greater drug surface area is exposed to the 
dissolution media, resulting in increased dissolution rate 
and bio availability 
1
. Valsartan is an angiotensin II 
receptor antagonist used in the management of 
hypertension 
2
. Valsartan is an antihypertensive drug 
having low aqueous solubility of 0.021mg/ml and low 
bioavailability of 23%. The aim of current research 
work was to enhance solubility and dissolution of poorly 
water soluble drug. 
MATERIALS AND METHODS: 
Valsartan was gift sample received from Hetero Drugs, 
Hyderabad. Other excipients include Avicel PH 102, 
Aerosil 200, Propylene glycol (PG), polyethylene glycol 
600 (PEG600), Tween 80. All reagents used were of 
analytical grade.  
Methods 
Saturation solubility studies  
Saturation solubility studies of Valsartan were carried 
out in distilled water, propylene glycol, PEG 600 and 
Tween 80. Saturated solutions prepared in above 
vehicles were kept in an orbital shaker (Remi motors 
Pvt. Ltd Mumbai, India.) for 48 h at 25 °C. The 
solutions were then filtered and drug content was 
determined using UV- VIS spectrophotometry 
(Shimadzu 1800, Japan) at 250 nm. . From these results, 
the solubility of valsartan in the respective liquid vehicle 
was calculated. Each experiment was carried out in 
triplicate 
3
. 
Preparation of liquisolid formulations  
This drug solution or suspension is incorporated into 
specific quantity of carrier material which should 
possess sufficient absorption properties. The resulting 
wet mixture is then converted into a dry–looking, non 
adherent, free-flowing and readily compressible powder 
by the simple addition and mixing of a calculated 
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amount of coating material having high adsorptive 
properties. 
Evaluation of liquisolid formulations 
Characterization of flow properties of liquisolid 
formulations 
Rania et al. (2008) suggested the pre compression 
evaluation parameters of Liquisolid powder systems. 
Flow properties of liquisolid systems were determined 
by estimating angle of repose, Carr’s index and 
Hausner’s ratio. Angle of repose was measured by fixed 
funnel method. Bulk density and taped density were also 
determined for the calculation of Hausner’s ratio and 
Carr’s index.  
Calculation of liquid load factor (Lf): Load factor is 
calculated by dividing weight of liquid medication (W) 
to weight of carrier material (Q) and is given by:                            
Lf=W/Q 
Percentage yield of liquisolid formulation: 
The percentage yield of the liquisolid system was 
determined using the following equation: 
% Yield=L/ Lo x 100 
Where, L = weight of prepared liquisolid formulation 
and Lo = total expected weight of formulation. 
Drug Content:  
Calculated amount of liquisolid powder formulation 
equivalent to single dose is dissolved in methanol and 
analysed for drug content using UV-visible 
spectrophotometer at 257nm. 
In vitro Dissolution Study:  
In-vitro drug release from liquisolid formulations is 
determined using USP Type II Dissolution Apparatus 
(paddle type). The dissolution study was carried out in 
900ml phosphate buffer pH 7.4 at 37°C ± 2 °C and 50 
rpm. At regular time intervals, aliquots of 5 ml samples 
were withdrawn up to 60min and the dissolution 
medium was replaced with 5ml fresh dissolution 
medium to maintain sink conditions. The samples were 
filtered through Whatman filter paper no. 1 and analysed 
for drug content after suitable dilution using UV-Visible 
spectroscopy. Finally, cumulative percentage drug 
release is calculated for all formulations. 
Optimization of prepared liquisolid formulations 
The liquisolid formulation with better dissolution profile 
and good flow properties of powder was optimized and 
selected for further solid state characterization. 
Solid state characterization of optimized liquisolid 
formulation 
Scanning Electron Microscopy 
SEM studies are performed to study surface morphology 
of drug as well excipients also confirm whether drug is 
present in crystal form or molecularly solubilized form. 
Fourier Transform Infrared spectroscopy (FTIR) 
FTIR studies are performed to study the compatibility of 
drug and other excipients in formulation by comparing 
drug and formulation spectra. 
RESULTS AND DISCUSSION: 
Saturated solubility studies for drug 
Saturated solubility studies were performed to select 
suitable non-volatile solvent in which drug dissolves to 
prepare liquid medication. 
Preparation of liquisolid formulations of Valsartan 
After screening several non-volatile solvents propylene 
glycol, polyethylene glycol (PEG) 600 and Tween 80 
were selected as liquid vehicles. Total 9 liquisolid 
formulations were prepared using Avicel as carrier 
material and Aerosil as coating material and shown in 
table below. 
Table 1: Saturation solubility studies of Valsartan in 
various non-volatile solvents 
Non-volatile solvent Solubility of valsartan 
(mg/ml) 
Distilled water 0.021 
Phosphate buffer pH7.4 0.955 
Polyethylene glycol 200 60.87 
Polyethylene glycol 400 65.22 
Polyethylene glycol 600 72.68 
Propylene glycol 83.71 
Tween 80 94.26 
Table 2: Various Liquisolid formulations of Valsartan 
Formulation 
Code 
Valsartan 
(mg) 
PEG 
600 
(mg) 
Propylene 
Glycol (mg) 
Tween 
80(mg) 
Avicel 
(MCC) 
(mg) 
Aerosil 
200(mg) 
Formulation 
weight(mg) 
VLS 1 40 100 - - 100 60 300 
VLS 2 40 110 - - 120 60 330 
VLS 3 40 120 - - 150 60 370 
VLS 4 40 - 100 - 100 60 300 
VLS 5 40 - 110 - 120 60 330 
VLS 6 40 - 120 - 150 60 370 
VLS 7 40 - - 100 100 60 300 
VLS 8 40 - - 110 120 60 330 
VLS 9 40 - - 120 150 60 370 
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Evaluation of liquisolid formulations of Valsartan 
Table 3: Flow properties characterization of liquisolid formulations of Valsartan 
Formula
tion 
Code 
Bulk density 
(mg/ml) 
Tapped 
density 
(mg/ml) 
Carr’s 
Index 
Haussner’s 
ratio 
Angle of 
repose(θ) 
Load 
factor 
Percentage 
yield (%) 
VLS 1 0.331 0.431 23.21 1.302 35.5 1.4 98.2 
VLS 2 0.343 0.448 23.41 1.306 31.6 1.25 98.6 
VLS 3 0.355 0.451 21.28 1.346 27.8 1.06 99.1 
VLS 4 0.324 0.433 25.17 1.336 35.8 1.4 98.1 
VLS 5 0.353 0.448 21.20 1.269 32.5 1.25 98.7 
VLS 6 0.361 0.459 21.35 1.271 27.2 1.06 99.4 
VLS 7 0.336 0.432 22.22 1.285 35.7 1.4 98.6 
VLS 8 0.363 0.447 18.79 1.231 31.8 1.25 98.9 
VLS 9 0.382 0.458 16.59 1.198 26.8 1.06 99.5 
 
Drug content 
Drug content of Valsartan liquisolid formulations were determined and given in below table. 
Table 4: Drug content of Valsartan liquisolid formulations 
Formulation Code Drug Content (%) 
VLS 1 90.05 
VLS 2 91.43 
VLS 3 95.33 
VLS 4 91.45 
VLS 5 93.89 
VLS 6 94.19 
VLS 7 92.88 
VLS 8 94.66 
VLS 9 96.78 
 
In Vitro Dissolution Study:  
In vitro drug release i.e cumulative percent drug release was calculated for all valsartan capsules prepared by liquisolid 
technique and was compared with pure drug formulations. 
Table 5: In vitro drug release of Valsartan liquisolid formulations 
Time 
(min) 
Pure 
drug VLS 1 VLS 2 VLS 3 VLS 4 VLS 5 VLS 6 VLS 7 VLS 8 VLS 9 
5 5.77 28.43 29.65 30.78 31.66 32.55 33.67 34.88 34.98 35.11 
10 7.98 30.76 32.66 34.66 35.88 37.23 38.54 39.55 40.66 42.44 
15 10.65 45.66 46.32 48.54 49.55 50.43 51.87 53.66 54.75 55.32 
30 15.22 67.44 69.65 70.22 71.64 72.15 73.88 76.89 79.54 80.34 
45 21.45 71.56 74.71 75.54 76.34 77.97 78.43 79.55 80.43 82.51 
60 27.82 83.74 85.52 86.31 87.48 88.76 89.22 93.64 94.43 98.77 
 
From the results of in vitro drug release it was observed 
that liquisolid formulation VLS9 showed better release 
profiles compared to that of pure drug. The mechanism 
for enhanced drug release postulated in liquisolid 
systems include increased surface area, improved 
wettability of drug particles due to reduction in 
interfacial tension which lead to increased aqueous 
solubility of the drug in microenvironment surrounding 
system. The reason may be due to greater wettability 
property of hydrophilic solvent Tween 80 having 
surfactant property of reducing interfacial tension. 
Valsartan within the liquisolid system is completely 
dissolved in Tween 80 and is located in the powder 
substrate still as solubilised, molecularly dispersed state. 
Thus the surface area of drug available for release is 
much greater than that of drug particles available in 
directly compressed tablets.  
Solid state characterization of optimized liquisolid 
formulation 
Scanning Electron Microscopy 
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SEM studies were conducted for drug, excipients as well 
as for optimized liquisolid formulation. The results of 
SEM studies revealed that crystalline form of drug has 
been converted to amorphous state. 
 
                                                                                   
                                    Figure1: SEM of Valsartan           Figure 2: SEM of VLS9 Formulation               
Fourier Transform Infrared spectroscopy (FTIR) 
 
Figure 3: a. Valsartan b. Aerosil 200  c. VLS9 formulation 
 
Results of FTIR showed that characteristic peaks in 
VLS 9 liquisolid formulation contained both peaks that 
of pure drug and Aerosil indicating no interaction 
between drug and excipients occurred. 
CONCLUSION: 
Successfully liquisolid formulations of valsartan was 
prepared using with remarkable improvement in 
dissolution profile and thus proved the potential of 
liquisolid technique as safer, efficacious method in 
enhancing solubility as well dissolution profile of poorly 
water soluble drugs.  
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